{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:00:25Z","timestamp":1785416425115,"version":"3.56.0"},"reference-count":15,"publisher":"Cambridge University Press (CUP)","issue":"5","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"unspecified","delay-in-days":14,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Cardiol Young"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"S104795112611289X_as1\">\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Venous thromboembolism prevalence amongst paediatric patients with CHD has increased over the years. Enoxaparin\u2019s favourable pharmacokinetic and pharmacodynamic properties, paired with less intensive monitoring parameters, make it a desirable treatment option. Currently, reported enoxaparin dosing strategies and their correlation to therapeutic anti-Xa levels are variable for infants aged 2 to 12 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S104795112611289X_as2\">\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This retrospective chart review evaluated the percentage of patients who achieved initial target anti-Xa levels on therapeutic enoxaparin. Patients were divided into standard-dose enoxaparin of 1 mg\/kg every 12 hours and high-dose enoxaparin of 1.5 mg\/kg every 12 hours.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S104795112611289X_as3\">\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Eighty-five patients were included in this study with similar demographics. More patients in the high-dose group achieved initial therapeutic levels of enoxaparin (36 (69%) vs 5 (15%);\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001). The time between initial dose of enoxaparin and first therapeutic anti-Xa level was longer in the standard-dose group (87 hrs (IQR 41 to 112) vs 24 hrs (IQR 16 to 40;\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001)), and there was no difference in the incidence of minor bleeding (6 (18%) vs 4 (7.7%);\n                      <jats:italic>p<\/jats:italic>\n                      = 0.18) or major bleeding (1 (3%) vs 0 (0%);\n                      <jats:italic>p<\/jats:italic>\n                      = 0.39), respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S104795112611289X_as4\">\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>High-dose enoxaparin in infants with CHD resulted in a higher percentage of initial anti-Xa target attainment and a decreased time to target anti-Xa level, with no difference in bleeding. Our study suggests it may be safe and effective to dose enoxaparin higher in infants with CHD; however, further studies should confirm these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1017\/s104795112611289x","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:34:41Z","timestamp":1778834081000},"page":"955-959","update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":0,"title":["Optimal dosing of enoxaparin in children with CHD less than 1 year of age"],"prefix":"10.1017","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8280-6922","authenticated-orcid":false,"given":"Katelyn R.","family":"Price","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/050fhx250","id-type":"ROR","asserted-by":"publisher"}],"name":"Children\u2019s Healthcare of Atlanta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hania","family":"Zaki","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/050fhx250","id-type":"ROR","asserted-by":"publisher"}],"name":"Children\u2019s Healthcare of Atlanta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haseena","family":"Hussain","sequence":"additional","affiliation":[{"name":"Wellstar Kennestone Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Sterner-Allison","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/050fhx250","id-type":"ROR","asserted-by":"publisher"}],"name":"Children\u2019s Healthcare of Atlanta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Giannopoulos Figg","sequence":"additional","affiliation":[{"name":"Atrium Health Wake Forest Baptist"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afrin","family":"Jahan","sequence":"additional","affiliation":[{"name":"Children\u2019s Healthcare of Atlanta Arthur M Blank Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Woods","sequence":"additional","affiliation":[{"name":"Children\u2019s Healthcare of Atlanta Inc"},{"name":"Emory University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua W.","family":"Branstetter","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/050fhx250","id-type":"ROR","asserted-by":"publisher"}],"name":"Children\u2019s Healthcare of Atlanta"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"S104795112611289X_ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2004.06.021"},{"key":"S104795112611289X_ref14","first-page":"689","article-title":"Evaluation of a pediatric enoxaparin dosing protocol and the impact on clinical outcomes","volume":"25","author":"Wiltrout","year":"2020","journal-title":"J Pediatr Pharmacol Ther"},{"key":"S104795112611289X_ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2017.00146"},{"key":"S104795112611289X_ref2","doi-asserted-by":"publisher","DOI":"10.1097\/BPB.0000000000000053"},{"key":"S104795112611289X_ref4","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2021-054649"},{"key":"S104795112611289X_ref5","doi-asserted-by":"publisher","DOI":"10.1542\/pir.2019-0026"},{"key":"S104795112611289X_ref6","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2308"},{"key":"S104795112611289X_ref8","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2008-2052"},{"key":"S104795112611289X_ref15","first-page":"1729","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"20","author":"Schulman","year":"2022","journal-title":"J Thromb Haemost"},{"key":"S104795112611289X_ref9","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1284"},{"key":"S104795112611289X_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2004.12.020"},{"key":"S104795112611289X_ref13","first-page":"43","article-title":"Utility of anti-Xa monitoring in children receiving enoxaparin for therapeutic anticoagulation","volume":"10","author":"Leung","year":"2005","journal-title":"J Pediatr Pharmacol Ther"},{"key":"S104795112611289X_ref12","first-page":"128","article-title":"A critical evaluation of enoxaparin dose adjustment guidelines in children","volume":"24","author":"Dinh","year":"2019","journal-title":"J Pediatr Pharmacol Ther"},{"key":"S104795112611289X_ref11","doi-asserted-by":"publisher","DOI":"10.1017\/S1047951109990564"},{"key":"S104795112611289X_ref7","doi-asserted-by":"publisher","DOI":"10.1097\/PCC.0000000000000623"}],"container-title":["Cardiology in the Young"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S104795112611289X","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T11:34:41Z","timestamp":1782128081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S104795112611289X\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S104795112611289X"],"URL":"https:\/\/doi.org\/10.1017\/s104795112611289x","relation":{},"ISSN":["1047-9511","1467-1107"],"issn-type":[{"value":"1047-9511","type":"print"},{"value":"1467-1107","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"\u00a9 The Author(s), 2026. Published by Cambridge University Press","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}}]}}